| Description | Ezutromid (BMN 195) is a translation modulator of Small utrophin (EC50: 0.4 uM). Ezutromid is an orally bioavailable small molecule that transcriptionally upregulates the utrophin gene, increasing both utrophin mRNA and protein. Through this action, Ezutromid increases muscle function in dystrophin-deficient MDX mice, a mouse model of muscular dystrophy. |
| Target activity | Small utrophin:0.4 μM |
| Synonyms | BMN 195, VOX-C1100, 依珠曲米, SMT C1100 |
| molecular weight | 337.39 |
| Molecular formula | C19H15NO3S |
| CAS | 945531-77-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 12 mg/mL (35.57 mM), Sonication is recommended. H2O: < 1 mg/mL (insoluble or slightly soluble) |
| References | 1. Tinsley JM et al. PLoS One. 2011 May 6;6(5):e19189., 2. Tinsley J et al. J Clin Pharmacol. 2015 Jun;55(6):698-707., 3. Guiraud S et al. Hum Mol Genet. 2015 Aug 1;24(15):4212-24.,www.ncbi.nlm.nih.gov/pubmed/25935002 |